Document is current
Any future updates will be listed below
-
Authors
Cunningham, Niamh
Shepherd, Scott
Mohammed, Kabir
Lee, Karla A.
Allen, Mark
Johnston, Stephen
Kipps, Emma
McGrath, Sophie
Noble, Jillian
Parton, Marina
Ring, Alistair
Turner, Nicholas C.
Okines, Alicia F. C. https://orcid.org/0000-0002-2068-2593
- License Information
-
More Information
Article History
Received: 20 April 2022
Accepted: 31 July 2022
First Online: 17 August 2022
Declarations
:
: Financial interests: Alicia Okines has received research funding from Pfizer and Roche; speakers fees from Pfizer, Lilly, Seagen, Gillead and Astra Zeneca; advisory boards for Roche, Seagen and Astra Zeneca and travel support from Lilly and Astra Zeneca. Alistair Ring has received research funding from PUMA and honoraria for advisory boards and speaker fees from Roche, Seagen, AZ-Daiichi-Sankyo. Stephen Johnston has received advisory board honoraria and research funding from PUMA. Nicholas Turner has received advisory board honoraria from Astra Zeneca, Bristol-Myers Squibb, Lilly, Merck Sharpe and Dohme, Novartis, Pfizer, Roche/Genentech, GlaxoSmithKline, Zentalis pharmaceuticals, Repare therapeutics, Arvinas and research funding from Astra Zeneca, BioRad, Pfizer, Roche/Genentech, Merck Sharpe and Dohme, Guardant Health, Invitae, Inivata, Personalis, Natera.
: The study was approved by the Royal Marsden NHS Trust committee for clinical research as a service evaluation (Ref. SE768).
: No consent was required for the use of link-anonymised patient data.
: Not relevant.
